Monoclonal Anti-ALPP Antibody, Human IgG1 (P1H05)

사용자 리뷰
제품 번호/규격
가격
Availability
수량
ALP-MY2719-100ug
$350.00
In Stock - Delivery in 2-3 business days
ALP-MY2719-1mg (500ug X 2)
$2310.00
In Stock - Delivery in 2 weeks
총 항목 수 제품 금액$ 0

제품 세부정보

  • Source

    Chimeric Monoclonal Anti-ALPP Antibody, Human IgG1 (P1H05) is recombinantly expressed in HEK293. It consists of mouse variable regions genetically fused to human IgG1 constant domains.

  • Antibody Type

    Recombinant Monoclonal

  • Clone

    P1H05

  • Isotype

    Human IgG1, Kappa

  • Host Species

    Mouse

  • Reactivity

    Human

  • Specificity

    Specifically recognizes Human ALPP protein.

  • Application

    Application
    Recommended Use / Performance
    ELISA
    1-2 ng/mL
  • Purification

    Protein A purified.

  • Aggregation

    Less than 5%, as determined by SEC-MALS.

  • Concentration

    Please refer to the Certificate of Analysis (CoA).

  • Form

    Lyophilized

  • Formulation

    Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4) containing 0.01% PF68, with trehalose as protectant.

    Please contact us for customized product forms or formulations.

  • Reconstitution

    Please refer to the Certificate of Analysis (CoA) for specific instructions.

  • Shipping

    Lyophilized product is shipped at ambient temperature.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • Notices

    Product Specific Notices: For research use only.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

고객님도 확인한 상품

데이터 표시

  • Bioactivity-ELISA

     ALPP ELISA

    Immobilized Human ALPP Protein, His Tag (Cat. No. ALP-H52H3) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-ALPP Antibody, Human IgG1 (P1H05) (Cat. No. ALP-MY2719) with a linear range of 0.06-1 ng/mL (QC tested).

    Protocol

사용자 리뷰
댓글 남기기

FAQ

  • product

    Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?

    In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.


    Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.


    To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.


    To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.


    Supporting Document


배경 소개

Placental alkaline phosphatase (ALPP) is a membrane-bound enzyme normally restricted to placental tissue. However, it is aberrantly overexpressed in various solid tumors, including ovarian, testicular, and cervical cancers, making it a highly specific tumor biomarker. High-affinity anti-ALPP antibodies are essential for early clinical cancer diagnostics (IHC/serum screening) and the development of targeted therapies like antibody-drug conjugates (ADCs) and CAR-T cells.

프론티어 진행

 
의약품 개발 진행
  • 영어 이름:

    Alkaline phosphatase, placental type

  • 카테고리:

  • 상장 의약품 수:

    0 상세

  • 임상 의약품 수:

    1 상세

  • 최고 개발 단계:

    Phase 2 Clinical

연락하기
신약 후보물질 라이선싱
더 많이 알아보기
  • 기본 제품 정보
  • 제품 세부정보
  • 고객님도 확인한 상품
  • 데이터 표시
  • 사용자 리뷰
  • FAQ
  • 배경